Infectious Diseases Now, Journal Year: 2023, Volume and Issue: 54(1), P. 104831 - 104831
Published: Nov. 10, 2023
Language: Английский
Infectious Diseases Now, Journal Year: 2023, Volume and Issue: 54(1), P. 104831 - 104831
Published: Nov. 10, 2023
Language: Английский
iScience, Journal Year: 2023, Volume and Issue: 26(6), P. 106802 - 106802
Published: May 4, 2023
Breastmilk contains antibodies that could protect breastfed infants from infections. In this work, we examined if in breastmilk neutralize SARS-CoV-2 84 samples women were either vaccinated (Comirnaty, mRNA-1273, or ChAdOx1), infected with SARS-CoV-2, both and vaccinated. The neutralization capacity of these sera was tested using pseudotyped vesicular stomatitis virus carrying the Wuhan-Hu-1, Delta, BA.1 Omicron spike proteins. We found natural infection resulted higher neutralizing titers correlated positively levels immunoglobulin A breastmilk. addition, significant differences to produce observed between mRNA-based vaccines adenovirus-vectored ChAdOx1 COVID-19 vaccine. Overall, our results indicate naturally those potentially provide protection infection.
Language: Английский
Citations
4Journal of Perinatology, Journal Year: 2023, Volume and Issue: 44(1), P. 28 - 34
Published: Dec. 13, 2023
Language: Английский
Citations
4Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11
Published: Feb. 9, 2024
Background Facilitated by the inability to vaccinate, and an immature immune system, COVID-19 remains a leading cause of death among children. Vaccinated lactating mothers produce specific SARS-CoV-2 antibodies in their milk, capable neutralizing virus vitro . Our objective for this study is assess effect booster dose on antibody concentration viral neutralization plasma, infant stool. Methods Thirty-nine 25 infants were enrolled from December 2020 May 2022. Milk, maternal infants' stool collected at various time-points up 12 months following mRNA vaccination. A subgroup 14 received dose. levels capacities assessed. Results Booster vaccination led significantly higher IgG within human milk breastfed In VSV-gfp-SARS-CoV-2-S-gp, laboratory safe like pseudovirus, improved booster, with 90% increase plasma 60% neutralization. We found that post-booster was highly correlated level. support our correlation result, Protein G column depletion yielded significant reduction ( p = 0.04). Discussion The substantial post-booster, coupled decrease capabilities upon depletion, underscores efficacy doses augmenting response against milk.
Language: Английский
Citations
1International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10248 - 10248
Published: Sept. 24, 2024
At the beginning of pandemic, SARS-CoV-2 infection represented a great medical burden worldwide, as targeted and effective therapeutic options were lacking. This resulted in revival existing molecules increasing popularity over-the-counter nutritional supplements. Among latter, lactoferrin has been investigated an adjuvant COVID-19 therapy with conflicting results, mainly depending on different study designs. Considering that is one main components human breast milk anti-microbial anti-inflammatory activity, it conceivable such bioactive molecule could be supporting anti-SARS-CoV-2 therapy, especially infants pregnant women, two subpopulations have poorly evaluated clinical trials. narrative review intended to offer insight into literature lactoferrin’s biological functions protective effects against COVID-19, special focus women their infants.
Language: Английский
Citations
1npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)
Published: Aug. 27, 2024
Abstract Hybrid immunity against SARS-CoV-2 has not been well studied in pregnancy. We conducted a comprehensive analysis of neutralizing antibodies (nAb) and binding pregnant individuals who received mRNA vaccination, natural infection, or both. A third vaccine dose augmented nAb levels compared to the two-dose regimen infection alone; this effect was more pronounced hybrid immunity. There reduced anti-Omicron nAb, but maternal-fetal transfer efficiency remained comparable that other variants. Vaccine-induced nAbs were transferred efficiently than infection-induced nAbs. Anti-spike receptor domain (RBD) IgG associated with wild-type (Wuhan-Hu-1) following breakthrough infection. Both vaccination anti-RBD IgA, which durable anti-nucleocapsid IgA. IgA response attenuated pregnancy non-pregnant controls. These data provide additional evidence augmentation humoral immune responses
Language: Английский
Citations
0Early Human Development, Journal Year: 2024, Volume and Issue: 198, P. 106126 - 106126
Published: Sept. 27, 2024
Language: Английский
Citations
0Vaccines, Journal Year: 2023, Volume and Issue: 11(11), P. 1643 - 1643
Published: Oct. 26, 2023
COVID-19 vaccination during pregnancy protects infants against symptomatic COVID-19. Vaccination of lactating mothers may offer additional protection, but our understanding immune responses in breast milk is limited. We, therefore, performed a single-center prospective cohort study who received mRNA primary vaccine series to evaluate the durability, breadth, and neutralizing capacity antibody milk. Spike IgG- IgA-binding antibodies ancestral SARS-CoV-2 serum were quantified over 9 months using Meso Scale Discovery (MSD) V-PLEX assays, titers compared four variants concern (Alpha, Beta, Delta, Gamma) at single time point. Neutralizing Omicron BA.4/5 before after pseudovirus-neutralization assay. Eleven either Pfizer BNT162b2 (7/11) or Moderna mRNA-1273 (4/11) series. IgG IgA increased following each dose, peaking 1-4 weeks completion. Titers remained significantly elevated for 7-9 months, except which returned baseline within 1 month. Furthermore, binding all included detected collected 1-3 However, while induced strong response more modest milk, it did not induce specimen type. This demonstrates that maternal enhance protection through via IgA-binding-and-neutralizing antibodies; although, variant-specific boosters be required optimize protection.
Language: Английский
Citations
1Infectious Diseases Now, Journal Year: 2023, Volume and Issue: 54(1), P. 104831 - 104831
Published: Nov. 10, 2023
Language: Английский
Citations
0